The article you requested is
Relapse and Rehospitalization: Comparing Oral and Depot Antipsychotics
J Clin Psychiatry 2003;64(suppl 16):14-17
© Copyright 2017 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
A review of studies that compared conventional oral and depot antipsychotic medications highlighted
the following points. Mirror-image studies in which patients served as their own controls provided
evidence of substantial benefit for depot injectable medications. The randomized clinical trials
did not, in general, support the findings of significant decrease in relapse rates between these 2 routes
of administration. Across the studies reviewed, the 1-year relapse rate for long-acting depot medication
was 27% compared with 42% for patients who received oral medication. The 27% risk of relapse
in patients who received guaranteed depot medication suggests that relapse is not always driven by
noncompliance. In the only study that lasted for 2 years, the risk of relapse decreased substantially in
the depot-treated patients, suggesting that risk of noncompliance may be a more important factor in
relapse over extended periods of time. A recent formal meta-analytic review of depot medications
concluded that this route of administration resulted in clinical advantages in terms of global outcome.